亮丙瑞林联合曼月乐治疗子宫腺肌症的效果及对血清VEGF、MMP-2水平的影响  

Efficacy of leuprolide combined with mirena in the treatment of adenomyosis and its effect on serum VEGF and MMP-2 levels

作　　者：董小瑞 谢淑红 刘超 Dong Xiaorui;Xie Shuhong;Liu Chao(Department of Obstetrics and Gynecology,Jiaozuo Second People’s Hospital,the First Affiliated Hospital of Henan University of Technology,Jiaozuo 454000,China)

机构地区：[1]河南省焦作市第二人民医院河南理工大学第一附属医院妇产科,454000

出　　处：《中国实用医刊》2022年第2期113-116,共4页Chinese Journal of Practical Medicine

摘　　要：目的:分析亮丙瑞林联合曼月乐治疗子宫腺肌症的效果及对血清血管内皮生长因子(VEGF)、基质金属蛋白酶2(MMP-2)水平的影响。方法:抽取2018年11月至2020年11月焦作市第二人民医院收治的子宫腺肌症患者206例,随机分为曼月乐组和亮丙瑞林组,每组103例。亮丙瑞林组予以亮丙瑞林治疗,曼月乐组予以亮丙瑞林联合曼月乐治疗。比较两组疗效、症状改善时间、VEGF、MMP-2、子宫体积、痛经口述分级评分法(VRS)、月经量月经失血图(PBAC)评分、不良反应发生率。结果:曼月乐组总有效率(95.15%)较亮丙瑞林组(80.58%)高, P<0.05;曼月乐组症状改善时间较亮丙瑞林组短( P<0.05);治疗3个周期后,曼月乐组血清VEGF、MMP-2较亮丙瑞林组低( P<0.05);治疗3个周期,曼月乐组子宫体积较亮丙瑞林组小( P<0.05);治疗3个周期,曼月乐组痛经VAS、月经量PBAC评分较亮丙瑞林组低( P<0.05);曼月乐组不良反应发生率(6.80%)与亮丙瑞林组(8.74%)比较,差异未见统计学意义( P>0.05)。 结论:亮丙瑞林联合曼月乐治疗子宫腺肌症可提高疗效,降低VEGF、MMP-2等血清因子水平,改善痛经、月经量异常症状和子宫体积,且安全性良好。Objective To analyze the efficacy of leuprolide combined with mirena in the treatment of adenomyosis and its effect on serum levels of vascular endothelial growth factor(VEGF)and matrix metalloproteinase 2(MMP-2).Methods A total of 206 patients with adenomyosis in Jiaozuo Second People’s Hospital from November 2018 to November 2020 were randomly,and divided into mirena group and leuprolide group,with 103 patients in each group.Leuprolide group was given leuprolide,and mirena group was given leuprolide combined with mirena.The efficacy,symptom improvement time,VEGF,MMP-2,uterine volume,Visual Rating scale(VRS),pictorial blood loss assessment chart(PBAC),score and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the mirena group(95.15%)was higher than that of the leuprolide group(80.58%),P<0.05.The symptom improvement time of the mirena group was shorter than that of the leuprolide group(P<0.05).After 3 cycles of treatment,serum VEGF and MMP-2 in the mirena group were lower than those in the leuprolide group(P<0.05).After 3 cycles of treatment,the uterine volume of mirena group was smaller than that of the leuprolide group(P<0.05).After 3 cycles of treatment,VRS and PBAC scores in the mirena group were lower than those in the leuprolide group(P<0.05).The incidence of adverse reactions in the mirena group(6.80%)was compared with the leuprolide group(8.74%),there was no significant(P>0.05).Conclusions Leuprolide combined with mirena in the treatment of adenomyosis can improve the efficacy,reduce the expression of VEGF,MMP-2 and other serum factors,improve dysmenorrhea,abnormal menstrual volume and uterine volume,with good safety and high clinical application value.

关 键 词：亮丙瑞林 曼月乐 子宫腺肌症 症状改善时间 子宫体积 

分 类 号：R711.71[医药卫生—妇产科学]